Moreover, the introduction of more refined imaging assessments and the use of molecular biology tests to identify specific biomarkers, such as MSI/MSS, Ras mutations, BRAF mutations, and HER2 amplification, have become crucial in determining appropriate management strategies for colon cancer [3,42,43,44,45]. Here, BRAF is linked to malignant colon neoplasm.